Cellectis S.A., the genome engineering company, announced today that it entered into an agreement with Lexicon Genetics Incorporated by which Lexicon granted Cellectis a worldwide, non-exclusive commercial sublicense to use isogenic DNA technology for homologous recombination in eukaryotic cells by double-stranded break methodology.
